Foghorn Therapeutics Inc FHTX

$2.02 -0.90 (-30.82%)

Valuation

Market cap
173,404,000
Revenue TTM
$30,910,000
Net income TTM
$-74,280,000
PE ratio
0.00
Forward PE
—
Profit margin
-240.31%
Debt to equity
0.00

Trading

Volume
2,546,300
Avg volume
671,648
Day's range
$1.99 – $2.91
Shares out
59,385,000
Stochastic %K
9%
Beta
3.01
Analysts
Strong Sell
Price target
$11.44

Price

Company profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell...

Show more

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 586 3100
Website
https://foghorntx.com
Address
99 Coolidge Avenue, Suite 500, Watertown, United States

Latest news

Stocktwits

KryptonResearch14 Oct 3, 8:59 PM
$FHTX Foghorn Therapeutics and Eli Lilly walked away from their lead oncology program Thursday. Foghorn cut about 40 percent of its workforce the same day. The drug was FHD-909, a SMARCA2 degrader aimed at lung and other solid tumors carrying SMARCA4 mutations. Phase 1 showed it was generally safe, but the efficacy was not there. CEO Adrian Gottschalk: the SMARCA2/4 synthetic lethality "has not translated into the level of efficacy required." The 2021 Lilly partnership, valued at up to $1.6B, will not be extended. Headcount goes from 106 to about 65, at a $2.3M restructuring charge. The tape reacted in premarket: down 44 percent Thursday to around 2. The counterpoint Foghorn is selling: the cuts extend its cash runway into the second half of 2029, funding its own blood-cancer, prostate, breast-cancer and oral inflammatory programs.
0 replies
Kingcrab33333 Oct 3, 8:57 PM
$FHTX
0 replies
topstockalerts Oct 2, 8:31 PM
Foghorn Therapeutics shares fell to $2 in afternoon trading, extending a two-day selloff after the company and Eli Lilly said they would not advance FHD-909 (LY4050784) into dose expansion following a Phase 1 review that found SMARCA2/4 synthetic-lethality biology did not produce sufficient clinical efficacy. The companies also abandoned a separate selective SMARCA2 degrader program, effectively ending their collaboration. Analyst downgrades intensified the pressure. Wedbush cut Foghorn to Neutral from Outperform and slashed its price target to $2 from $10, while BTIG downgraded the stock to Neutral from Buy. TD Cowen also moved to Hold from Buy, while H.C. Wainwright, Guggenheim and Stifel each cut their targets to $5 from $13, $12 and $12, respectively. Citizens shifted to Market Perform. Foghorn is restructuring with a roughly 40% workforce reduction aimed at extending its cash runway into the second half of 2029. $FHTX
0 replies
StocktwitsNews Oct 2, 6:12 PM
FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80% $FHTX $LLY https://stocktwits.com/news/equity/markets/fhtx-stock-extends-sell-off-after-lilly-collaboration-ends-wedbush-slashes-target-by-80/cZDjlfYRBKS
0 replies
prismmarketview Oct 2, 5:54 PM
A week of sharp turns across the PRISM Emerging Biotech Index: 48-month AMT-130 data from $QURE , a $110 million raise at $PYXS , a November 22 PDUFA date ahead for $CAPR , a year-end colorectal update planned at $ONCY and a restructuring at $FHTX . https://prismmarketview.com/a-week-of-sharp-turns-across-the-prism-emerging-biotech-index/
0 replies
prismmarketview Oct 2, 4:43 PM
PRISM Mid-Day Movers: NextGen Tech & AI and New Energy are Today’s Leaders. QTREX Quantum Ltd. (NASDAQ: $QTEX ) shares surged 44.02% to $1.13 in midday trading Friday, gaining $0.3454 from Thursday’s $0.7846 close. 5E Advanced Materials Inc. (NASDAQ: $FEAM) shares climbed 19.66% to $3.865 in midday trading Friday, gaining $0.635 from Thursday’s $3.23 close. Other Notable Movers: NeuroOne ($NMTC ) up 12% EVgo Inc. ($EVGO ) up 10% Foghorn Therapeutics ($FHTX ) down -22% Stock prices are from October 2, 2026 at 12:15p.m. and are subject to change. https://prismmarketview.com/prism-mid-day-movers-nextgen-tech-ai-and-new-energy-are-todays-leaders/
0 replies
anachartanalyst Oct 2, 4:04 PM
$FHTX https://anachart.com/wp-content/uploads/2026/10/1790957067_soc-img.jpg
0 replies
OpenOutcrier Oct 1, 8:02 PM
RECAP 10/1 -Neg Comments: $LIFE - Bear Cave $LIFE - HNTRBRK $SE - DBS $FHTX - Citizens $NSP - Equity Dispatch $SGML - JPM Live Breaking trading news www.openoutcrier.com
0 replies